NeoGenomics Faces Legal Setback as RaDaR Assay Injunction Continues

Friday, 12 July 2024, 15:24
An appeals court recently upheld the injunction against NeoGenomics regarding its RaDaR assay, a cancer test, amidst a patent dispute with Natera. The ongoing legal battle has significant implications for both companies and raises questions about intellectual property rights and market competition. With the injunction remaining in place, NeoGenomics faces challenges in the commercialization of its innovative medical technology.
Seeking Alpha
NeoGenomics Faces Legal Setback as RaDaR Assay Injunction Continues

RaDaR Assay Injunction Affirmed by Appeals Court

An appeals court has recently affirmed an injunction against NeoGenomics in a patent dispute with Natera. The injunction relates to the sale of NeoGenomics' cancer test, RaDaR assay.

Legal Implications and Market Impact

The decision has raised concerns about intellectual property rights and market competition within the medical diagnostics industry.

While the legal battle continues, NeoGenomics may face challenges in commercializing its innovative technology.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe